Company news

Tenax Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

September 14, 2022

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

May 22, 2022

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

May 17, 2022

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

March 30, 2022

Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

March 29, 2022

Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

January 30, 2022

Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

January 11, 2022

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

January 3, 2022

Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update

November 15, 2021

Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)

October 5, 2021

Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update

August 16, 2021

Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

August 11, 2021

Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

July 6, 2021

Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update

May 16, 2021

Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ”

April 8, 2021

Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders

April 6, 2021

Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update

March 30, 2021

Tenax Therapeutics, Inc. Expands Board of Directors

March 1, 2021

Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med

January 18, 2021

Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update

November 15, 2020

Tenax Therapeutics Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020

November 9, 2020

Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Corporation

October 14, 2020

Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting

October 1, 2020

Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

August 30, 2020

Tenax Therapeutics Reports Second Quarter 2020 Results and Provides Business Update

August 16, 2020

Tenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD

July 19, 2020

Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules

July 5, 2020

Tenax Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

June 1, 2020

Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 “HELP Study” of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

April 8, 2020

Tenax Therapeutics Announces $2.75 Million Registered Direct Offering Priced At-the-Market

March 11, 2020

Tenax Announces the Addition of Mayo Clinic Expert, Dr. Barry Borlaug, to Scientific Advisory Board

February 20, 2020

Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial

October 30, 2019

← Newer news releases

Calls

Decks

The 5 newest of 14 decks. Every deck is listed under its year.